18F-NOS PET/CT Scan for Parkinson's Disease
What You Need to Know Before You Apply
What is the purpose of this trial?
The research study is being conducted to test how a specialized type of Positron Emission Tomography (PET/CT) scan could potentially be useful in diagnosing or monitoring treatment in people with Parkinson's disease. If the subject decide to be in this study he/she will have a PET/CT scans using an imaging drug called 18F-NOS which will be used to measure inflammation in the brain.
Will I have to stop taking my current medications?
The trial protocol does not specify if you need to stop taking your current medications. However, if you are in the healthy control group, you cannot use any central nervous system (CNS) drugs within 30 days of screening.
Is the 18F-NOS PET/CT scan safe for humans?
The 18F-NOS PET/CT scan has been evaluated in humans, including patients after heart transplantation, to measure its safety and effectiveness in imaging inflammation. While specific safety data for Parkinson's Disease is not detailed, the scan has been used in human studies without reported safety issues, suggesting it is generally safe for use in humans.12345
How does the 18F-NOS PET/CT scan treatment differ from other treatments for Parkinson's disease?
The 18F-NOS PET/CT scan is unique because it is a non-invasive imaging method that measures neuroinflammation in the brain, which is thought to be a key factor in Parkinson's disease. Unlike traditional treatments that focus on managing symptoms, this scan helps to visualize and understand the underlying inflammation, potentially leading to better-targeted therapies.23467
What data supports the effectiveness of the drug [18F]NOS for Parkinson's Disease?
Who Is on the Research Team?
Jacob Dubroff, MD, PhD
Principal Investigator
University of Pennsylvania
Are You a Good Fit for This Trial?
This trial is for people aged 18-75 with Parkinson's disease or healthy individuals interested in brain inflammation research. Participants must understand the study and agree to its procedures. Those with neuropsychiatric disorders can join if it doesn't risk their safety or participation, as judged by an investigator.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Imaging
Participants undergo one experimental 18F-NOS PET/CT scan to measure brain inflammation
Follow-up
Participants are monitored for safety and effectiveness after imaging
What Are the Treatments Tested in This Trial?
Interventions
- [18F]NOS
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Pennsylvania
Lead Sponsor